Nele Van Der Steen obtained her PhD at the University of Antwerp

Our “Amsterdam/Antwerp-shared” student Nele Van Der Steen has successfully discussed her PhD Thesis on “The labyrinth of cMET and EGFR signaling in non-small cell lung cancer” at the University of Antwerp. Promotors: Prof. Dr. P. Pauwels Prof. Dr. G.J. Peters, and Dr. E. Giovannetti.

Of note, Nele has managed to publish all the chapters of her Thesis: Congratulations!

  1. Crizotinib sensitizes the erlotinib resistant HCC827GR5 cell line by influencing lysosomal function. Van Der Steen N, Keller K, Dekker H, Porcelli L, Honeywell RJ, Van Meerloo J, Musters R , Kathmann  I, Frampton AE, Liu DSK, Ruijtenbeek R, Rolfo C, Pauwels P, Giovannetti E, Peters GJ. Journal of Cell Physiology 2020, in press.
  2. The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies. Van Der Steen N, Zwaenepoel K, Mazzaschi G, A Luirink R, P Geerke D, Op de Beeck K, Hermans C, Tiseo M, Van Schil P, Lardon F, Germonpré P, Rolfo C, Giovannetti E, J Peters G, Pauwels P. Molecules. 2019 Dec 4;24(24). pii: E4443. doi: 10.3390/molecules24244443.
  3. Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. Biochem Pharmacol. 2019 Aug;166:128-138. doi: 10.1016/j.bcp.2019.05.014.
  4. Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. Cavazzoni A, La Monica S, Alfieri R, Ravelli A, Van Der Steen N, Sciarrillo R, Madeddu D, Lagrasta CAM, Quaini F, Bonelli M, Fumarola C, Cretella D, Digiacomo G, Tiseo M, Peters GJ, Ardizzoni A, Petronini PG, Giovannetti E. Oncotarget. 2017 May 23;8(32):53068-53083. doi: 10.18632/oncotarget.18087.
  5. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC. Van Der Steen N, Mentens Y, Ramael M, Leon LG, Germonpré P, Ferri J, Gandara DR, Giovannetti E, Peters GJ, Pauwels P, Rolfo C. Clin Lung Cancer. 2018 Jan;19(1):35-41. doi: 10.1016/j.cllc.2017.06.010. Epub 2017 Jul 6.
  6. Resistance Mechanisms to AZD9291 and Rociletinib-Letter. Van Der Steen N, Rolfo C, Pauwels P, de Langen AJ, Peters GJ, Giovannetti E. Clin Cancer Res. 2017 Jul 15;23(14):3966. doi: 10.1158/1078-0432.CCR-17-0167
  7. Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. Van Der Steen N, Deben C, Deschoolmeester V, Wouters A, Lardon F, Rolfo C, Germonpré P, Giovannetti E, Peters GJ, Pauwels P. World J Clin Oncol. 2016 Dec 10;7(6):425-432. doi: 10.5306/wjco.v7.i6.425.
  8. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope? Van Der Steen N, Rolfo CD, Pauwels P, Peters GJ, Giovannetti E. J Clin Oncol. 2017 Feb 20;35(6):692-693. doi: 10.1200/JCO.2016.70.1987
  9. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. Onco Targets Ther. 2016 Oct 6;9:6065-6074. eCollection 2016.
  10. cMET Exon 14 Skipping: From the Structure to the Clinic. Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ, Hong DS, Cappuzzo F, Hirsch FR, Rolfo C. J Thorac Oncol. 2016 Sep;11(9):1423-32. doi: 10.1016/j.jtho.2016.05.005.